BluePath Capital Management LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

BluePath Capital Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 171.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,580 shares of the company’s stock after buying an additional 999 shares during the quarter. BluePath Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,260,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sawyer & Company Inc grew its stake in Eli Lilly and Company by 88.0% during the fourth quarter. Sawyer & Company Inc now owns 12,154 shares of the company’s stock valued at $9,383,000 after acquiring an additional 5,689 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Eli Lilly and Company by 0.9% in the 4th quarter. Pinnacle Bancorp Inc. now owns 5,269 shares of the company’s stock valued at $4,068,000 after purchasing an additional 46 shares during the period. Redhawk Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 4.8% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 6,868 shares of the company’s stock valued at $5,302,000 after purchasing an additional 313 shares in the last quarter. Rockingstone Advisors LLC increased its holdings in shares of Eli Lilly and Company by 912.5% in the fourth quarter. Rockingstone Advisors LLC now owns 3,088 shares of the company’s stock worth $2,384,000 after purchasing an additional 2,783 shares during the period. Finally, ARS Wealth Advisors Group LLC raised its position in shares of Eli Lilly and Company by 1.3% in the fourth quarter. ARS Wealth Advisors Group LLC now owns 2,113 shares of the company’s stock worth $1,631,000 after buying an additional 27 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on LLY shares. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Citigroup increased their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.6 %

NYSE LLY opened at $758.70 on Friday. The firm has a market cap of $720.25 billion, a PE ratio of 82.02, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $612.70 and a 1-year high of $972.53. The stock has a 50-day moving average of $784.03 and a 200-day moving average of $856.70. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company announced that its Board of Directors has approved a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.